Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial

BACKGROUND: Young survivors of cancer are at increased risk for cancers that are related to human papillomavirus (HPV), primarily caused by oncogenic HPV types 16 and 18. We aimed to examine the immunogenicity and safety of the three-dose series of HPV vaccine in young survivors of cancer. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Landier, Wendy, Bhatia, Smita, Wong, F Lennie, York, Jocelyn M, Flynn, Jessica S, Henneberg, Harrison M, Singh, Purnima, Adams, Kandice, Wasilewski-Masker, Karen, Cherven, Brooke, Jasty-Rao, Rama, Leonard, Marcia, Connelly, James A, Armenian, Saro H, Robison, Leslie L, Giuliano, Anna R, Hudson, Melissa M, Klosky, James L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087203/
https://www.ncbi.nlm.nih.gov/pubmed/34767765
http://dx.doi.org/10.1016/S2352-4642(21)00278-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087203/
https://www.ncbi.nlm.nih.gov/pubmed/34767765
http://dx.doi.org/10.1016/S2352-4642(21)00278-9

Ejemplares similares